Chronic sinusitis
Conditions
Interventions
Observation group:Fudosteine 400mg, tid, continuous treatment for 14 days
Control group:Placebo 400mg, tid, 14d
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Comply with CRS diagnostic criteria; (2) Aged 18 to 70 years, and the VAS score and/or the post-nasal drip VAS score of the chronic sinusitis is greater than 5 points; (3) The main clinical manifestations are nasal congestion, olfactory loss, rhinorrhea, head suffocation or pressure. Nasal endoscopy mainly manifests as hypertrophy of the inferior turbinate and/or middle turbinate, purulent secretion in the posterior nostril, nasopharynx or in the lower nasal passage, middle nasal passage, and no atrophic rhinitis.
Exclusion criteria
Exclusion criteria: (1) Patients with obvious anatomical abnormalities in the sinus and nasal passage complex; (2) An acute upper respiratory tract infection or an acute CRS author before treatment; (3) Patients with serious systemic diseases such as cancer; (4) Those who are allergic to this product; (5) Liver and kidney dysfunction and heart disease, blood disease patients; (6) Those who are unable to cooperate with mental illness or other reasons; (7) Women during pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nasal secretion traits before and after treatment;VAS score;SNOT-20;LK endoscopy score;Clinical efficacy; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-1?IL-4?IL-8?IFN-??TNF;MUC5AC?MUC5B; | — |
Countries
China
Contacts
Public ContactLiu Feng
Outcome results
None listed